石药集团(01093.HK) 公布,附属石药集团巨石生物制药开发的治疗用生物制品3.3类注射用奥马珠单抗(商品名:恩益坦)用于治疗中至重度持续性过 敏性哮喘的新适应症已获中国国家药品监督管理局上市许可批准。这是恩益坦在内地获批的第二个适应症。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-10 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.